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A b s t r a c t
Introduction: Zero-contrast percutaneous coronary intervention (zero-PCI) is a new method for prevention of contrast-induced 
acute kidney injury (AKI) in patients with chronic kidney disease (CKD). However, evidence for its feasibility, safety and clinical utility 
is limited to reports of single cases or series of patients.
Aim: To present outcomes of zero-PCI in patients with severe CKD, including hemodialysis subjects, who were treated with this 
procedure in order to preserve their renal function.
Material and methods: Twenty-nine zero-PCIs were performed, mostly as a staged procedure, in 20 patients with advanced 
CKD. In this group, 4 patients were treated with hemodialysis but presented preserved residual renal function. The estimated medi-
an risk for contrast-induced AKI in non-dialysis patients was 26% (26–57%). 
Results: Zero-PCI was feasible in each intended patient, including those with complex left main stenosis or lesion within a saphe-
nous vein graft, and there was no specific complication associated with this technique. After the procedure, the factual AKI prevalence 
was 10% and no patient required renal replacement therapy. Three of 4 hemodialysis patients preserved their residual renal function. 
During the median follow-up of 3.2 (1.2–5.3) months no patient experienced an acute coronary event or required revascularization. 
Conclusions: Zero-PCI is a safe and promising method to preserve renal function in patients with CKD and hemodialysis pa-
tients. Such an approach is feasible even in complex coronary lesions and yields good clinical outcomes in mid-term observation.
Key words: renal insufficiency, contrast-induced nephropathy, acute kidney injury, zero-contrast percutaneous coronary inter-
vention.
S u m m a r y
Zero-contrast percutaneous coronary intervention (zero-PCI) is a new strategy for prevention of contrast-induced acute 
kidney injury (AKI). This study presents outcomes of 29 zero-PCIs performed in 20 patients with severe chronic kidney dis-
ease. Zero-PCI was feasible in each intended patient and there was no specific complication associated with this technique. 
The estimated median risk of AKI of 26% (26–57%) before zero-PCI dropped to the observed prevalence of 10%, and during 
the median follow-up of 3.2 (1.2–5.3) months no patient experienced an acute coronary event or required revascularization.
Introduction
Contrast-induced acute kidney injury (AKI) is a  se-
vere complication of percutaneous coronary interven-
tion (PCI) in patients with chronic kidney disease (CKD) 
and is responsible for various adverse outcomes such 
as deterioration of renal function, necessity of dialysis, 
prolonged hospitalization and increased mortality [1, 2]. 
The risk of AKI is particularly high in CKD patients with 
multiple comorbidities including diabetes mellitus, con-
gestive heart failure, hemodynamic instability, reduced 
plasma volume and anemia [3, 4]. Since the incidence 
of AKI increases almost linearly with the amount of con-
trast, every method allowing contrast volume reduction 
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may protect renal function [2, 3]. Zero-contrast PCI (ze-
ro-PCI) is a new emerging method for the prevention of 
AKI among patients with CKD [5]. However, despite ini-
tial promising results, experiences in this approach are 
still limited to single cases or series of patients [5–14]. 
Moreover, it is not known if such an approach plays any 
positive role in preserving residual renal function in he-
modialysis patients. Since the procedure without con-
trast administration is demanding and may be associ-
ated with some potential complications, more evidence 
for its feasibility, safety and clinical utility is needed 
before it will be accepted as a daily practice by a wide 
interventional community. 
Aim
The aim of this retrospective analysis was to present 
outcomes of zero-PCI in patients with severe CKD, includ-
ing hemodialysis subjects, who underwent this proce-
dure in order to preserve their renal function. 
Material and methods
Patients with renal failure requiring percutaneous 
revascularization were treated with zero-PCI if they met 
one of the following criteria: (i) their estimated glomeru-
lar filtration rate (eGFR, by the Modification of Diet in Re-
nal Disease equation) was less than 45 ml/min/1.73 m2; 
(ii) they previously experienced contrast-induced AKI; or 
(iii) they were treated with hemodialysis but presented 
preserved residual renal function defined as urine out-
put ≥ 500 ml/day [15]. The main exclusion criteria were: 
ST-segment elevation myocardial infarction (STEMI), 
shock, chronic total occlusion and terminal chronic re-
nal failure with no residual diuresis. However, patients 
after recent STEMI who required further revasculariza-
tion and AKI prevention were also qualified for zero-PCI 
as a  staged procedure. Patients with non-ST-segment 
elevation myocardial infarction (NSTEMI) were suitable 
for such an intervention if their infarct-related artery 
was patent without obvious thrombus on the initial 
coronary angiography. Previous coronary artery bypass 
grafting (CABG) and the need for rotational atherecto-
my in non-tortuous artery were not exclusion criteria. 
Individual risk of AKI before zero-PCI was estimated ac-
cording to the Mehran risk score with the assumption 
that contrast dye is not used [3]. Contrast-induced AKI 
was defined as an increase in the serum creatinine level 
of more than 0.5 mg/dl (44 μmol/l) or an increase of at 
least 25% in the level from baseline within 72 h after the 
procedure [1]. 
Stable patients with known significant renal impair-
ment underwent ultra-low contrast coronary angiogra-
phy where the intended maximum contrast volume was 
pre-defined as less than or equal to 15 ml – details on how 
to perform such an examination have been summarized 
elsewhere [16]. However, unstable patients with acute 
coronary syndrome usually first underwent standard in-
terventions and then, if they needed further revascular-
ization, zero-PCI was performed as a staged procedure. 
For zero-PCI, coronary angiography was analyzed in de-
tail and the suitable angiographic images were displayed 
alongside the active fluoroscopy screen as a  reference 
– the guidewires were inserted according to these refer-
ence images. The procedure was guided by intravascular 
ultrasound (IVUS), i.e. IVUS identified the lesion length, 
determined balloon and stent diameters, and landing 
zones for stent implantation, as well as verified and doc-
umented the final PCI effect. Landing zones were deter-
mined at the first non-diseased vessel segments close to 
the lesion or at segments with plaque burden less than 
50% in cases with diffuse lesions. The reference diame-
ters for selection of balloons and stents were determined 
by the maximum lumen diameter of the distal landing 
zone – if another stent had to be proximally placed, the 
proximal landing zones was a reference. The stent length 
was based on the distance between the distal and prox-
imal landing zones and was measured with a calibrated 
Volcano IVUS probe. The PCI result was assessed in IVUS 
by calculating the stent expansion which corresponded 
to the ratio of the minimum stent area over the mean 
of the proximal and distal stent reference lumen areas 
multiplied by 100% (percentage). A detailed description 
of the zero-contrast method and its procedural options 
may be found elsewhere [16]. Due to legal issues, at the 
end of procedure, a  single injection of small contrast 
volume (usually 5 ml) was performed in each patient to 
document the angiographic PCI result and lack of com-
plications (e.g. distal perforation or embolization). Other 
indications for contrast injection during the intervention 
included: chest pain, persistent drop in blood pressure, 
new electrocardiographic changes and any suspicion of 
complications. To become familiar with this technique, 
operators had to undergo a training program which re-
lied on the guidewire insertion and balloon as well as 
stent positioning without contrast usage during sever-
al standard PCIs (i.e. under ultimate control of contrast 
injections) and then, for maintenance of the skill, they 
repeated such a procedure periodically. 
All patients provided their informed written consent 
for the procedure and the treatment strategy was accept-
ed by the institutional review board.
Statistical analysis
Continuous variables were presented as mean ± stan-
dard deviation or median and interquartile range where 
it was appropriate according to normality tests. Categor-
ical variables were presented as numeric values and per-
centages. Differences in renal function parameters before 
and after zero-PCI were compared using Student’s paired 
t-test or the Wilcoxon signed-rank test. The threshold 
probability of p < 0.05 was taken as the level of statisti-
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cal significance. All analyses were performed using NCSS 
12 Statistical Software (2018). NCSS, LLC. Kaysville, Utah, 
USA, ncss.com/software/ncss.
Results
The study group consisted of 20 patients aged 73.7 
±12.8 years with severe renal impairment (eGFR 24.8 
±12.5 ml/min/1.73 m2) who underwent zero-PCI for 
prevention of AKI – 4 of these subjects were chronically 
treated with hemodialysis. Thirteen (65%) patients were 
admitted due to acute coronary syndromes, i.e. 3 (15%) 
with STEMI, 6 (30%) with NSTEMI and 4 (20%) with un-
stable angina. Three (15%) patients were hospitalized 
because of heart failure, 2 (10%) due to sustained ven-
tricular tachycardia and 2 (10%) were admitted for elec-
tive PCI. Table I presents patients’ characteristics. Before 
zero-PCI, ultra-low contrast coronary angiography was 
performed in 9 patients including hemodialysis subjects 
(median contrast volume: 13 (11–24) ml). In 2 patients 
with advanced CKD, who were admitted for elective in-
tervention, coronary angiography was performed during 
previous hospitalization. However, 9 unstable patients 
with acute coronary syndrome first underwent standard 
coronary angiography and PCI of the infarct related ar-
tery with median contrast volume of 150 (70–200) ml, 
and consequently two of them developed contrast-in-
duced AKI requiring temporal hemodialysis – since they 
all required further revascularization, staged zero-PCI 
was performed after renal function stabilization. 
In general, zero-PCI was performed within 29 coro-
nary arteries in 20 patients with advanced CKD. Sixteen 
of these subjects underwent staged procedures with 
a median time of 6 (5–8) days after the first intervention. 
Multi-vessel zero-PCI was done in 7 cases. One patient 
with severe calcified lesions was treated with rotational 
atherectomy but another presenting obstruction within 
the saphenous vein graft required insertion of a  distal 
protection device – both procedures were done without 
contrast injection. 
After each intervention, due to legal issues, a small 
amount of contrast dye was injected to confirm the final 
result and exclude complications (median contrast vol-
ume: 5 (3.5–9) ml). Procedural data concerning zero-PCI 
are presented in Table II.
According to the Mehran risk score, the estimated 
median risk for contrast-induced AKI before zero-PCI was 
26% (26–57%) in non-dialysis patients. The creatinine 
and eGFR levels did not differ significantly before and 
after the intervention (mean change: 0.1 ±0.31 mg/dl, 
p = 0.2; and –0.7 ±10.9 ml/min/1.73 m2, p = 0.8, re-
spectively). However, in 2 patients the creatinine value 
slightly exceeded the pre-defined threshold for AKI after 
zero-PCI; hence the AKI prevalence turns out to be 10%. 
Importantly, 2 patients who previously developed con-
trast-induced AKI requiring hemodialysis after standard 
Table I. Patients’ characteristics
Parameter Overall group
Clinical characteristics:
Age [years] 73.7 ±12.8
Males 12 (60)
ACS 13 (65)
Hemodialysis patients 4 (20)




LVEF (%) 42.2 ±12.8
Previous MI 2 (10)
Previous PCI 1 (5)
Previous CABG 3 (15)
Dyslipidemia 7 (35)
Current smoking 1 (5)
Baseline laboratory values:
Troponin T 202.8 (89.5–995.5)
WBC [× 103/µl] 8.1 (7.2–12.2)
RBC [× 106/µl] 3.9 ±0.8
Hemoglobin [g/dl] 11.6 ±2.3
HCT (%) 35.9 ±6.7
PLT [× 103/µl] 225 (184–257)
Creatinine [mg/dl] 3.2 ±1.9
eGFR [ml/min/1.73 m2] 24.8 ±12.5
Coronary artery disease:
One-vessel disease 0 (0)
Two-vessel disease 7 (35)
Three-vessel disease 13 (65)
Left main disease 1 (5)
Bypass graft disease 2 (10)
Values are n (%), mean ± SD or median (Q1–Q3). ACS – acute coronary syn-
drome, CHF – congestive heart failure, VHD – valvular heart disease, LVEF – left 
ventricular ejection fraction, MI – myocardial infarction, PCI – percutaneous cor-
onary intervention, CABG – coronary artery bypass graft, WBC – white blood 
cells, RBC – red blood cells, HCT – hematocrit, PLT – platelets, eGFR – estimated 
glomerular filtration rate. Coronary artery disease was recognized if the diame-
ter stenosis was at least 50%.
coronary angiography and PCI did not experience AKI af-
ter zero-PCI. In 1 patient, the troponin T value exceeded 
the level for type 4A myocardial infarction, yet without 
clinical consequences (IVUS and the final single contrast 
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administration did not reveal abnormalities) [17]. In 1 pa-
tient with NSTEMI, the final small contrast injection re-
vealed distal embolization which was subsequently treat-
ed with anticoagulants and antiplatelet agents. During 
the median follow-up period of 3.2 (1.2–5.3) months, one 
woman with severe pulmonary hypertension died after 
6 months due to right ventricular heart failure – death 
not related to the procedure. 
Four hemodialysis patients had a median diuresis of 
900 (763–1150) ml/day before and 875 (263–1000) ml/
day after the intervention (p = 0.8), and 3 of them pre-
served their residual renal function after zero-PCI. In one 
of these patients, who underwent a  3-vessel zero-PCI, 
the renal function improved within some weeks, i.e. the 
diuresis increased from 800 to 1000 ml/day and the rate 
of dialyses was reduced from 3 to 2 times per week. An-
other patient lost the residual renal function within sev-
eral weeks after hospitalization, i.e. his diuresis dropped 
from 1000 to 100 ml/day. Table III presents the summary 
of patients’ outcomes and medications.
Table II. Zero-contrast PCI
Procedural data Overall group
Number of vessels treated with  
zero-contrast PCI
29
Staged PCI 24 (83)
Time between coronary angiography  
and staged PCI [days]
6 (5–8)
Left main artery 1 (3)
Left anterior descending artery 11 (38)
Left circumflex artery 10 (34)
Right coronary artery 6 (21)
Saphenous vein graft 1 (3)
Diameter stenosis (%) 85.3 ±8.7
Lesion length [mm] 35.4 ±19.6
Lesion area [mm2] 2.9 (2.6–3.4)
Lesion plaque burden (%) 76 (70–79)
Minimal stent area [mm2] 6.5 (5.3–7.6)
Stent expansion (%) 95 (88–103)
Guide wires 2 (1–2)
Number of stents 2 (1–2)
Total stent length [mm] 42.9 ±19.7
Stent diameter [mm] 3 (2.5–3.5)
Pre-dilation 42 (88)
Post-dilation 41 (85)
Rotational atherectomy 1 (5)
Distal embolic protection 1 (5)
Procedure time [min] 69 ±26
Radiation dose [mGy] 1485 ±828
Final contrast injection [ml] 5 (3.5–9)
Values are n (%), mean ± SD or median (Q1–Q3). PCI – percutaneous coronary 
intervention. Pre-dilation and post-dilation relate to each implanted stent (total 
number of stents is 48).




Change in creatinine [mg/dl] 0.1 ±0.31
Change in eGFR [ml/min/1.73 m2] –0.7 ±10.9
AKI after zero-contrast PCI 2 (10)
Renal replacement therapy  
(non-dialysis patients)
0 (0)
Periprocedural MI 1 (5)
Distal embolization 1 (5)
Follow-up:
Follow-up period 3.2 (1.2–5.3)
ACS 0 (0)
Stent thrombosis 0 (0)
Repeat revascularization 0 (0)
Stroke 0 (0)















Oral hypoglycemic agent 5 (25)
Insulin 5 (25)
Values are n (%), mean ± SD or median (Q1–Q3). PCI – percutaneous coronary 
intervention, eGFR – estimated glomerular filtration rate, AKI – acute kidney 
injury, MI – myocardial infarction, ACS – acute coronary syndrome, ACEI/ARB – 
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. 
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Discussion
Zero-contrast PCI is a new promising approach in the 
prevention of AKI in patients with severe CKD. Howev-
er, current evidence for its feasibility and safety is based 
on case reports and one retrospective study involving 
31 patients [5–14]. Therefore, any new clinical data ver-
ifying this method provides valuable information on its 
effectiveness, which is paramount for its wider dissem-
ination among the interventional community. Until now, 
zero-contrast techniques were employed only in stable 
patients, and subjects with acute coronary syndromes 
were not considered for such interventions [6]. This retro-
spective analysis summarizes the mid-term outcomes of 
zero-PCI carried out in a heterogeneous group of patients 
involving both stable subjects and unstable ones with 
acute coronary syndromes. The rationale for such an 
approach was to reduce renal function deterioration in 
a wide range of high-risk patients, e.g. in individuals with 
severe CKD who recently underwent standard primary 
PCI or experienced contrast-induced AKI. The estimated 
median probability of AKI in non-dialysis patients was 
26% according to the Mehran risk score, but this risk was 
calculated with the assumption that contrast dye was 
not used – if these patients were treated with standard 
PCI using 100–200 ml of contrast medium, the median 
risk would increase to 57%. Thanks to the zero-contrast 
approach, the factual risk of AKI was reduced to 10% and 
no patient required renal replacement therapy. Of note, 
two patients who previously developed contrast-induced 
AKI after standard coronary angiography and PCI did not 
experience AKI again after zero-PCI. 
There was one periprocedural “laboratory” myocardi-
al infarction, yet without any clinical sequelae [17]. At the 
end of the procedure, due to legal issues, each patient 
obtained a small contrast volume (usually 5 ml) to docu-
ment the final PCI result. Such a small contrast amount 
should not pose any relevant problem in terms of renal 
function, but it allowed us to recognize distal emboliza-
tion in one patient with NSTEMI which was undetectable 
in IVUS, and consequently an adequate drug therapy was 
employed. During the median follow-up period of 3.2 
(1.2–5.3) months, no patient experienced acute coronary 
event or required revascularization. 
In the study group, there were 4 hemodialysis pa-
tients with preserved residual renal function. Three of 
these patients maintained their renal function, but in 
one patient the diuresis significantly dropped within 
some weeks after hospitalization. The latter patient had 
just started elective hemodialysis during the index hospi-
talization and other causes beside the coronary interven-
tion might play a role in this loss of function. Namely, an 
initiation of hemodialysis by itself may suppress diuresis 
in some patients, which is associated with a number of 
factors, e.g. type of dialysis, hydration, congestive heart 
failure, diabetes and medications [18–20]. Therefore, it is 
unlikely that zero-PCI was the cause of the loss of renal 
function in this subject. In another hemodialysis patient, 
who underwent a 3-vessel zero-PCI, the left ventricular 
function improved along with residual renal function and 
after some weeks the rate of dialysis was reduced. To the 
best of our knowledge, there is no report on zero-PCI in 
patients on chronic hemodialysis, but such an approach 
may help in preservation of their remaining renal func-
tion. Importantly, it has been demonstrated that the 
residual renal function is a prognostic and independent 
factor of quality of life, morbidity and survival in dialy-
sis patients, and therefore every protective measure to 
preserve this function is worth considering [21]. Never-
theless, suitable prospective studies should address this 
strategy before it is recommended in clinical practice. 
Study limitations
Several limitations of this study need to be acknowl-
edged. This is a  small and non-randomized study per-
formed in a  single center, which involved a  heteroge-
neous group of patients, i.e. both stable and unstable 
ones, who faced a very high risk of AKI. Some patients 
were initially treated with standard procedures in the 
acute phase but zero-PCI was employed during further 
steps of revascularization as a  staged intervention to 
protect their renal function. Although this makes the 
data non-homogeneous, it shows that the employment 
of zero-PCI at any stage of revascularization may bring 
benefit to patients with severe renal dysfunction. Each 
zero-PCI was done without contrast usage; nevertheless, 
at the end of the procedure usually one confirmatory in-
jection of median contrast volume of 5 (3.5–9) ml was 
performed due to legal issues. Such a small amount of 
dye should not induce AKI, but this needs to be tested 
in further experiments. Finely, for more objective assess-
ment of the real clinical benefit of the zero-contrast ap-
proach, randomized trials on large groups of patients are 
necessary. Despite all these limitations, the results of this 
study show that zero-PCI is feasible and is not associated 
with any specific complications. 
Conclusions
This retrospective analysis shows that zero-contrast 
PCI is a  safe and effective method to preserve renal 
function in patients with severe renal impairment and 
hemodialysis subjects. Moreover, it yields good clinical 
outcomes in mid-term observation. Since the procedure 
was based on IVUS imaging, it allowed us to optimize 
stent implantation with good procedural results, and 
consequently no stent thrombosis occurred during the 
follow-up. Thanks to the training program, the learning 
curve for the experienced operators was steep and there 
was no conversion to standard PCI in the study group. 
Therefore, if the patient’s profile or clinical situation in-
dicates that the risk of AKI is high, zero-PCI should be 
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considered as a preventative solution – this also refers to 
dialysis patients with residual renal function. 
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